Core Scientific (CORZ) EBITDA Margin (2021 - 2026)

Core Scientific has disclosed EBITDA Margin across 6 years of filings, most recently posting 269.36% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 269.36%, down 21021.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 143.48% (down 8402.0% YoY), and the FY2025 annual result was 76.98%, down 4916.0% from the prior year.
• EBITDA Margin came in at 269.36% for Q1 2026 at Core Scientific, down from 147.28% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 30.8% in Q1 2024 to a low of 637.54% in Q2 2022.
• The 5-year median for EBITDA Margin is 59.15% (2025), against an average of 125.85%.
• Across the five-year window, EBITDA Margin tumbled 65816 bps in 2022 and jumped 64500 bps in 2023, its largest moves.
• Core Scientific's EBITDA Margin stood at 524.6% in 2022, then soared by 101 bps to 2.77% in 2023, then tumbled by 2585 bps to 68.89% in 2024, then plunged by 114 bps to 147.28% in 2025, then slumped by 83 bps to 269.36% in 2026.
• The last three EBITDA Margin figures came in at 269.36% (Q1 2026), 147.28% (Q4 2025), and 67.56% (Q3 2025), per Business Quant data.